Radiation therapy saves countless lives in the fight against brain tumors, but it extracts a devastating price from the very tissue it passes through. For the majority of patients who survive more than six months after high-dose cranial radiotherapy, cognitive decline is not a possibility but a probability, with estimates in recent literature ranging from 50 to 90 percent of long-term survivors experiencing measurable deficits. Now, a team of researchers at the University of Texas Health Science Center in Houston reports that a water-soluble derivative of the soccer-ball-shaped carbon molecule known as [60]fullerene, or C60, can dramatically blunt this damage in mice. In a study published in the journal Biomedical Microdevices, the team shows that a single oral dose of their compound, dubbed C60-ser, given 24 hours after cranial irradiation restored spatial working memory and suppressed the chronic brain inflammation that radiation unleashes. The work, led by Naren Gundapaneni and senior authors Yuri Mackeyev and Sunil Krishnan, positions an exotic carbon nanomaterial as a serious candidate for protecting the brains of cancer patients, and perhaps even astronauts venturing into deep space.
The clinical problem the researchers set out to address is formidable. Ionizing radiation is a cornerstone of treatment for both primary and metastatic brain tumors in adults and children, yet deep-seated tumors cannot be irradiated without exposing healthy surrounding brain tissue. Many brain tumors are also radioresistant, forcing oncologists to escalate doses or re-irradiate, which compounds cumulative injury to normal tissue. Although modern techniques such as proton beam therapy, stereotactic radiosurgery, and intensity-modulated radiation therapy have sharpened the spatial precision of dose delivery, neurocognitive impairment still emerges, affecting verbal memory, motor dexterity, and processing speed. Patients treated for head and neck cancers, who receive substantial incidental doses to the brain, fare no better. The downstream consequences range from subtle learning and memory dysfunction to deficits in executive function and, in severe cases, dementia, a spectrum that profoundly undermines quality of life for survivors who may otherwise live for decades.
At the cellular level, the injury cascade begins with oxidative stress. Ionizing radiation shatters water molecules and biomolecules alike, generating free radicals and reactive oxygen species that trigger inflammatory signaling pathways and activate microglia, the brain’s resident macrophages. Once activated, these cells persist in a pro-inflammatory state, churning out cytokines that perpetuate the damage and suppress neurogenesis, particularly in the hippocampus, the seahorse-shaped structure indispensable for forming new memories. Reactive astrocytes and infiltrating peripheral immune cells amplify the cascade further, cementing a chronic neuroinflammatory microenvironment that links the initial radiation insult to progressive cognitive decline. This mechanistic chain suggested a therapeutic opportunity: if the oxidative burst could be quenched early, the downstream inflammation and cognitive damage might be prevented. That is precisely where the fullerene comes in.
C60 is a polyhedral caged carbon allotrome whose exceptional radical-scavenging ability stems from its pseudo-aromatic structure, in which π-electrons are delocalized across the entire carbon cage, giving the molecule an extraordinarily high electron affinity that allows it to accept and neutralize unpaired electrons. The trouble, historically, has been that pristine fullerenes are intensely hydrophobic and refuse to disperse in water, limiting any biological application. The Houston team circumvented this through an elaborate two-step chemical synthesis. First, serinol and dimethyl malonate were reacted to form serinol malonate, which was then acetylated to produce serinol malonamide tetraacetate. In the second step, C60 was cyclopropanated with this malonamide derivative in the presence of the base DBU, yielding a hexakis-adduct that was purified by liquid chromatography and then deacetylated with hydrochloric acid, neutralized to pH 6.5, and dialyzed to remove oligomeric and low-molecular-weight impurities. The resulting C60-ser was verified at 97.3 percent purity by HPLC and MALDI-ToF mass spectrometry, and, crucially, it dissolves readily in water and can be delivered orally.
Earlier work had shown that this particular derivative is orally bioavailable, crosses the blood-brain barrier, and persists in brain tissue for more than a week, an unusually favorable pharmacokinetic profile for a nanomaterial. But previous in vivo studies of fullerene radioprotection had focused on whole-body exposure models with readouts limited to survival, oxidative stress markers, and DNA damage. No study had directly asked whether a fullerene could protect cognition and dampen neuroinflammation after cranial irradiation. To answer that question, the researchers irradiated four-and-a-half-week-old male C57BL/6 mice with either 10 or 30 Gy targeted to a defined 7-millimeter region of the brain using a small-animal irradiator, sparing the eyes and oronasopharynx with lead shielding. Twenty-four hours later, the mice received either 700 milligrams per kilogram of C60-ser or a PBS vehicle by oral gavage. Two cohorts of animals were then tracked, with behavioral testing at approximately 45 days and again at 84 days after treatment.
The behavioral results were striking, if selectively so. Across the battery of tests, the most informative outcome came from the Y-maze spontaneous alternation task, which assesses spatial working memory dependent on the hippocampus and prefrontal cortex. Radiation produced a clear dose-dependent decline in performance: mean alternation percentages fell from 63.93 percent in unirradiated controls to 57.50 percent at 10 Gy and 54.69 percent at 30 Gy. In mice that received C60-ser, however, performance stayed above 60 percent across all groups, with the 30 Gy-treated animals actually averaging 64.28 percent, better than controls. Statistically, the interaction between radiation and treatment was significant, and post hoc testing confirmed that 30 Gy significantly impaired performance relative to controls while C60-ser treatment restored it to a level indistinguishable from unirradiated animals. The object-in-place and novel object recognition tasks, which engage the prefronal and perirhinal cortex in addition to the hippocampus, showed trends in the protective direction but did not reach significance, suggesting that the compound’s protection is most pronounced in hippocampally dependent tasks and at higher radiation doses.
At 84 days, the behavioral deficit had largely disappeared in all groups, an unexpected result the authors interpret cautiously. They ruled out carryover effects from repeated testing by comparing animals tested twice against those tested once and finding no difference, and they note that functional plasticity and partial cognitive recovery have been documented in human cancer patients four to six months after radiotherapy. What makes this discordance scientifically important is what the histology revealed. When the researchers examined the cornu ammonis 1 region of the hippocampus, the area most vulnerable to damaging insults and central to memory consolidation, they found that radiation had driven a dose-dependent increase in CD68-positive cells, a marker of activated microglia, and that this activation persisted for a full 84 days after exposure. The brain’s inflammatory machinery, in other words, never switched off, even when behavior appeared to recover.
The anti-inflammatory effect of C60-ser on this chronic activation was the study’s most convincing molecular finding. At the 45-day endpoint, two-way ANOVA revealed significant effects of radiation, of C60-ser treatment, and of their interaction on CD68 immunoreactivity. Mice given 30 Gy alone had significantly more CD68-positive cells than every other group, while mice given 30 Gy followed by C60-ser showed CD68 reactivity statistically indistinguishable from unirradiated controls. In the later cohort, C60-ser treatment again significantly reduced CD68 immunoreactivity, with the reduction reaching statistical significance in the 10 Gy comparison. Given prior evidence that eliminating or calming microglia after brain injury can meaningfully improve cognitive recovery by reversing chronic neuroinflammation, the authors argue that suppressing microglial activation is the most plausible mechanism through which C60-ser protects the irradiated brain, effectively intercepting the inflammatory cascade at its source rather than trying to repair damage after it has become entrenched.
Beyond the immediate findings, the study establishes a foundation with implications that extend well beyond the oncology clinic. Radiomitigative drugs are of intense interest to space agencies, because cosmic radiation on long-duration missions to Mars and beyond poses health risks that physical shielding alone cannot fully solve, and biological countermeasures such as C60-ser could become part of the astronaut toolkit. The authors are candid about the work’s limitations and future directions. The 700 mg/kg dose produced no overt toxicity, but it may exceed what is actually needed, so dose-optimization studies are warranted. All mice were male, and previous work suggests females may perform differently on memory tasks, potentially due to ovarian hormones, so sex-balanced designs are needed. The team also proposes adding complementary hippocampal tasks such as the Morris water maze, probing how specific inflammatory cell populations respond to the compound at different ages, testing its effects directly on cultured hippocampal neural stem cells, and evaluating the compound alongside emerging modalities like proton beams and boron neutron capture therapy. Y.M. and S.K. have filed a provisional patent on C60-ser as a radioprotector and radiomitigator, a signal that they intend to push the compound toward translational development. For now, the message is that a molecule shaped like a tiny geodesic sphere, once dismissed as an exotic curiosity of carbon chemistry, may hold the key to keeping the brain whole when radiation is unavoidable.
Subject of Research: A water-soluble [60]fullerene derivative (C60-ser) mitigating cranial radiation-induced neuroinflammation and cognitive dysfunction in mice
Subject of Research: Technology and Engineering
Article Title: Water-soluble fullerene derivatives mitigate cranial radiation-induced neuroinflammation and cognitive dysfunction
Article References: Gundapaneni, N., Hill, I., Cheung, L. W. T., Koushki, K., Fausnaught, A., Mai, P. M. Q., Vasan, A., Biswal, P., Tripathi, A., Pillai, A., Giridharan, V. V., Barichello, T., Mackeyev, Y., & Krishnan, S. (2026). Water-soluble fullerene derivatives mitigate cranial radiation-induced neuroinflammation and cognitive dysfunction. Biomedical Microdevices, 28(2), Article 36. https://doi.org/10.1007/s10544-026-00818-w
Image Credits: AI Generated
DOI: 10.1007/s10544-026-00818-w
Keywords: fullerene, C60, C60-ser, radiation, neuroprotection, cognitive impairment, neuroinflammation, microglia, radiotherapy, hippocampus, nanomedicine
Cite Scienmag News
APA
MLA
Chicago
Cassandra Pierce. (September 10, 2026). Fullerene derivatives ease brain inflammation after cranial radiation therapy. Scienmag. https://scienmag.com/fullerene-derivatives-ease-brain-inflammation-after-cranial-radiation-therapy/
Cassandra Pierce. “Fullerene derivatives ease brain inflammation after cranial radiation therapy.” Scienmag, 10 September 2026, https://scienmag.com/fullerene-derivatives-ease-brain-inflammation-after-cranial-radiation-therapy/. Accessed 10 September 2026.
Cassandra Pierce. “Fullerene derivatives ease brain inflammation after cranial radiation therapy.” Scienmag. September 10, 2026. https://scienmag.com/fullerene-derivatives-ease-brain-inflammation-after-cranial-radiation-therapy/
Copy citation
Download RIS
Tags: and reduce chronic brain inflammation. This research suggests promising applications in medical radiation therapy and space exploration.as neuroprotective agents that can mitigate radiation damageboth of whom face risks of radiation-induced brain inflammation and cognitive decline. The study highlights the potential of fullerene derivativesbrain tumor patients and astronauts exposed to space radiationbrain tumor radiotherapyC60-ser brain inflammation reductioncarbon nanomaterials in neuroprotectioncranial radiation therapy cognitive declinefullerene derivatives neuroprotectionnanomaterials in radiation damage preventionnanotechnology for brain tumor treatmentoxidative stress and inflammation in brain injurypost-radiation brain health strategiesradiation-induced cognitive deficitsrestore cognitive functionsspace radiation impact on brain tissuespecifically C60-serwater-soluble fullerene compounds
